
Zai Lab Ltd
Zai Lab Ltd (ZLAB)
웹사이트주가
시가총액
다음 일정Initiate first-line randomized Phase 3 in Q4 2026, by year-end, based on emerging dataZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3 · Trial initiation회사 보도자료 ↗
현금
차트 및 이벤트
핵심 임상
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3
DLL3
PreINDP1P2FilingApproved
PreINDP1P2FilingApproved
Approved
PreINDP1P2P3FilingApproved
기술 요약
기술 해석과 근거
상세 기술 해석
기술이 줄 수 있는 이점
대표 파이프라인 적용
임상 진행
예정 임상 일정
Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3
DLL3
PreINDP1P2FilingApproved
그 외 파이프라인
승인/상업화
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
과거 이력 · 중단/보류
자금 현황
주식 보유 현황·기관투자자
| 상태 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|